Deepinder Goyal’s Rs 85,000 Temple wearable is facing questions from doctors about its scientific credibility, The Economic Times reports. The dispute puts the relationship between Indian product ambition and verifiable evidence in focus. [2]

The claims and the response

Hindustan Times reported on 8 November that Goyal described the wearable as designed for a global market rather than specifically for India. India Today’s 9 November lead similarly attributes to him the distinction between a product made by an Indian startup and one made for Indian consumers. [5][1]

The Times of India reports Goyal’s response that the company did not make a medical claim. That is his stated position, not an independent assessment of the device. The supplied leads do not detail the doctors’ objections, the product’s underlying evidence or the precise claims being challenged. They therefore cannot establish either efficacy or failure. [3][2]

Sanatan Daily analysis

Building in India for customers abroad is not inherently at odds with national development. But market ambition and scientific credibility are separate questions. A global audience does not remove the need to explain what a device measures and what conclusions users can reasonably draw.

The constructive next step is clarity: distinguish the intended use from any health implication, and make supporting evidence accessible to scrutiny. For Indian innovation, credibility should be part of the product—not merely its defence.